Healthcare, Pharma & Life Sciences

Suzhou – November 08, 2026 -- Innovent Biologics (HKEX: 01801) said its PCSK9 antibody SINTBILO (tafolecimab) cut LDL-C by 65.19% at week 12 as monotherapy in the Phase 3 CREDIT-5 study, meeting the primary endpoint. The company plans to file a new-indication application with China's National Medical Products Administration (NMPA) "in the near future".

CREDIT-5 trial shows placebo-adjusted LDL-C drops above 58 points in both dosing regimens

The multi-center, randomized, double-blind, placebo-controlled study enrolled 198 Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia. Of these, 131 received tafolecimab and 67 received placebo. Patients were randomized 2:1:2:1 to tafolecimab 150 mg every two weeks (Q2W), placebo Q2W, tafolecimab 450 mg every four weeks (Q4W) or placebo Q4W, after a 4-week run-in during which lipid-lowering products were prohibited.

SHANGHAI – November 08, 2026 -- CureGene Pharmaceutical reported that its investigational P2Y12 antagonist Evategrel (CG-0255) produced comparable pharmacokinetics and platelet inhibition in Chinese and US healthy volunteers, clearing a key hurdle for running global trials in parallel. The data were presented as a poster at the American Heart Association (AHA) Scientific Sessions 2026 in Chicago, held November 6-9.

Two clinical pharmacology studies test ethnic and food effects on oral Evategrel

One study compared oral Evategrel pharmacokinetics (PK) and pharmacodynamics (PD) in Chinese and US participants. The second examined how food affects exposure to the oral formulation and its antiplatelet effect. Both used the same design, with one run in the United States and one in China.

NEW BRUNSWICK, N.J. – November 07, 2026 -- Johnson & Johnson reported that 96% of Sjögren's disease patients interviewed after its Phase 2 DAHLIAS study cited mouth dryness as a symptom, making it both the most frequent complaint and the improvement patients prioritized most. The company will present the findings among 23 nipocalimab abstracts at the American College of Rheumatology (ACR) Convergence 2026.

Four core symptoms reported by more than 70% of interviewed patients

Besides mouth dryness (96%), patients most often reported fatigue (92%), eye dryness (90%) and joint pain (73%). Among women, 49% reported vaginal dryness. Patients said they saw improvements across many of these symptoms during the treatment phase.

Sjögren's disease is a chronic, systemic, autoantibody-driven condition affecting approximately four million people worldwide. It is nine times more common in women than in men.

GUANGZHOU – November 07, 2026 -- POMDOCTOR LIMITED (NASDAQ: POM) has regained compliance with Nasdaq's $1.00 minimum bid price requirement, removing the immediate threat of delisting for its Class A ordinary shares.

The company received a compliance letter from The Nasdaq Stock Market LLC on November 5, 2026, confirming it meets Listing Rule 5450(a)(1). The Nasdaq Hearings Panel hearing originally scheduled for November 12, 2026 has been cancelled as a result.

Nasdaq issued a staff delisting determination on October 6 after 30 straight business days below $1.00

The compliance confirmation follows a staff delisting determination letter dated October 6, 2026. Nasdaq had found that the closing bid price of Pomdoctor's securities was below $1.00 per share for 30 consecutive business days.

Vancouver – November 07, 2026 -- InMed Pharmaceuticals has completed its merger with privately held Mentari Therapeutics, which closed private financings of approximately $490 million in gross proceeds immediately before the deal. The combined company operates as Mentari Therapeutics, Inc.

Shares begin trading as MTRI on Nasdaq Capital Market on November 9

The combined company's shares are expected to start trading at market open on Monday, November 9, 2026, under the ticker "MTRI" and the new CUSIP number 587157108. The stock previously traded on Nasdaq as INM.

$490 million financing includes $50.0 million in converted notes

The proceeds include the conversion of $50.0 million of previously issued convertible notes, plus accrued interest. Immediately before closing, the company also redomesticated from British Columbia, Canada, to the State of Nevada.

Berlin – November 07, 2026 -- The Marburger Bund is calling on the German government to scrap the increase in Medical Service (MD) audit quotas and hospital invoice thresholds planned for January 1, 2027. The doctors' association estimates the change would force hospitals to hire 1,500 to 3,000 additional staff nationwide.

Marburger Bund calls the current audit procedure neither practical nor economical

The demand comes from a resolution passed by the association's 148th General Assembly in Berlin. The resolution describes the existing audit-quota procedure as neither practical nor economically sensible.

Higher quotas would require one to two extra full-time staff per hospital

The association estimates each hospital would need to hire one to two full-time employees to handle the additional audits. Across all German hospitals, that adds up to 1,500 to 3,000 workers.

Berlin – November 07, 2026 -- Dr. Susanne Johna won a third term as 1st Chair of the Marburger Bund with 91 percent of delegate votes (202 of 222 valid ballots). Delegates voted at the association's 148th General Assembly in Berlin. No challenger ran for the post.

Johna extends a tenure that began in November 2019

Johna has led Germany's largest doctors' association since November 2019. Federal board members are elected for four years. Johna, 61, is an internist and hospital hygiene specialist. She works as a senior physician for hospital hygiene at St. Josefs-Hospital Rheingau in Rüdesheim. She also sits on the board of the German Medical Association (Bundesärztekammer) as vice president.

PLAINSBORO, N.J. – November 07, 2026 -- Novo Nordisk reported that adults with metabolic dysfunction-associated steatohepatitis (MASH) who started semaglutide 2.4 mg once weekly lost a statistically significant mean 18.9 lb (8.6 kg; about 8%) from baseline versus patients on resmetirom at six months, according to real-world data presented at AASLD The Liver Meeting 2026 in Denver.

PLATINUM-Truveta compares 2,873 semaglutide patients with 2,285 on resmetirom

The retrospective cohort study drew on de-identified electronic medical records from 30 US health systems in the Truveta database, covering June 2021 through March 2026. Semaglutide 2.4 mg was also associated with significantly greater reductions than resmetirom in AST and some cardiometabolic measures. Researchers assessed ALT, AST, body weight, HbA1c, platelets, triglycerides, HDL and LDL at three and six months.

REHOVOT, Israel – November 05, 2026 -- Evogene Ltd. (Nasdaq: EVGN; TASE: EVGN) will release its third-quarter 2026 financial results on Thursday, November 19, 2026, the computational chemistry company announced.

Management will host a conference call the same day at 9:00 AM Eastern Time (4:00 PM Israel time) to discuss the results. Attendance via Zoom requires advance registration.

Evogene will publish a full conference recording on its website a few days after the call

The company plans to make the entire conference available online shortly after the event, giving investors who miss the live session access to management's commentary.

BOSTON – November 06, 2026 -- Skyhawk Therapeutics has dosed the first U.S. patients in its global pivotal FALCON-HD study of SKY-0515 in Huntington's disease (HD). More than 50,000 doses have been administered to date across more than 30 study sites in 10 countries.

CenExel Colorado site opens U.S. dosing, with Beth Israel Deaconess next

Dosing in the U.S. began at the CenExel Movement Disorder Center in Colorado. Additional U.S. sites, including Beth Israel Deaconess Medical Center, are expected to begin dosing in the coming weeks. Samuel Frank, MD, Director of the HDSA Center of Excellence at Beth Israel Deaconess and a FALCON-HD investigator, expects dosing there before the end of 2026. He described Phase 1/2 results to date as very encouraging.